Article summary
Clinical updates from Compass Pathways and Helus Pharma from last week marked a significant step forward in the psychedelics development landscape, with new data emerging from late stage and mid stage programs targeting depressive disorders. The post Psychedelics Clinical Trial Update: Positive Results from Psilocybin and DMT on the Road for FDA Approval appeared first on Psychedelic Health.
Continue to the original publication for the complete article.